(Q36472437)

14 August 2017

1 reference

title

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer (English)

1 reference

14 August 2017

1 reference

4

Gabriel N Hortobagyi

1 reference

14 August 2017

3

Mien-Chie Hung

1 reference

14 August 2017

1

Rita Nahta

1 reference

14 August 2017

Dihua Yu

2

1 reference

PubMed ID

16683005

14 August 2017

Francisco J Esteva

series ordinal

5

1 reference

14 August 2017

1 May 2006

1 reference

Nature Clinical Practice Oncology

14 August 2017

1 reference

14 August 2017

3

1 reference

14 August 2017

269-280

1 reference

14 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/ncponc0509

14 August 2017

0 references

cites work

Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Targeted therapy in breast cancer: the HER-2/neu gene and protein

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Stability of HER-2/neu expression over time and at multiple metastatic sites

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Herceptin: mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Mechanism of action of trastuzumab and scientific update

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Muc4/sialomucin complex in the mammary gland and breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Lung cancer: intragenic ERBB2 kinase mutations in tumours

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Autoregulatory mechanisms in protein-tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Identification of a novel mitogen-inducible gene (mig-6): regulation during G1 progression and differentiation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Mig-6 is a negative regulator of the epidermal growth factor receptor signal

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Development of Herceptin resistance in breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Vaccination against the HER-2/neu oncogenic protein

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0509

7 January 2021

Identifiers

DOI

10.1038/NCPONC0509

1 reference

PubMed ID

16683005

Dimensions Publication ID

14 August 2017

0 references

1 reference

PubMed ID

16683005